

Figure S1. Time to VL <40 copies/mL and TND status **(A)** overall and **(B-C)** by baseline VL subgroups (observed analysis). All participants with VL <50 copies/mL at Week 144 were included. DTG, dolutegravir; FTC, emtricitabine; NE, not evaluable; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; TND, target not detected; VL, viral load.

